Blood tests to predict blood clots in people having chemotherapy for cancer
Studies blood clotting markers to predict clots in adults having chemotherapy.
Key facts
- Who runs it
- University of Dublin, Trinity College
- Where
- Ireland3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Prediction of Venous Thrombosis During chemotherapy-the PINPOINT Study
- Status
- Recruiting
- People taking part
- 380 people, planned
- Started
- 1 Oct 2025
- Expected to end
- 1 Sept 2029
- Type of study
- Observational
- Record updated
- 15 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with ovarian, lung, gastric or pancreatic cancer who are about to start chemotherapy. Blood tests will check clotting markers to predict blood clots.
- Age
- Over 18 years
- Sex
- All
- Disease stage
- Ovarian, lung, gastric or pancreatic cancer. Chemotherapy before or after surgery, chemotherapy for cancer that came back, or targeted therapy given with chemotherapy.
- Earlier treatment
- People must be scheduled to start a course of chemotherapy. They cannot have had chemotherapy or immunotherapy 4 weeks before the first blood sample.
Main reasons for not taking part
- A blood clot in a vein in the last 5 years (some clots linked to a central line are allowed)
- Serious bleeding needing hospital care or transfusion, outside surgery, in the last 5 years
- An inherited bleeding disorder, or known disseminated intravascular coagulation (a severe clotting disorder)
- Surgery within 2 weeks of the first blood sample, except port-a-cath placement or biopsy
- Currently taking long-term blood thinners such as LMWH, DOACs or Warfarin
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patients with a diagnosis of ovarian, lung, gastric or pancreatic cancer scheduled to undergo a course of chemotherapy who are undergoing adjuvant or neoadjuvant chemotherapy, or who are undergoing chemotherapy for relapsed disease or patients receiving targeted therapy in combination with chemotherapy
- Patients who are over 18 years of age
- Patients who are able to give full and informed written consent
Who cannot take part
- Prior history of a documented VTE event within the last 5 years (excluding central line associated events whereby patients completed anticoagulation > 3 months previously)
- Surgery within 2 weeks of first baseline sample (with the exception of porth-a-cath implantation or biopsy)
- Chemotherapy or immunotherapy 4 weeks before first baseline sample
- Currently receiving long term anticoagulant therapy (Low Molecular Weight Heparin(LMWH), Direct Oral Anticoagulants(DOACs), Warfarin). Patients receiving aspirin, ticlopidine, clopidogrel or LMWH at a prophylactic dosage for a short period (ie post cancer surgery or during short hospital stay) will be included provided they have completed thromboprophylaxis therapy at the first blood sampling time point
- Any history of significant haemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 5 years
- Familial bleeding diathesis
- Known diagnosis of disseminated intravascular coagulation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Cancer patients are at higher risk of getting a blood clot (known as venous thromboembolism (VTE)) especially during chemotherapy and some patients are more at risk than others. These clots can be prevented by using blood thinners (known as anticoagulants) but these are not suitable for everyone as they also carry a risk of bleeding. This study aims to identify which chemotherapy patients are most at risk of a blood clot and at what point in their treatment this is likely to happen. In this project biomarkers in the blood that are involved in blood clotting will be measured in cancer patients at four stages during chemotherapy to see how the biomarkers change during treatment. The blood samples for these tests are taken at the same time as the normal routine blood tests done before a chemotherapy cycle. Biomarker levels will be compared between those patients who subsequently get a VTE and those who do not get a VTE. This will help develop a biomarker based blood test to predict clots during chemotherapy. The biomarker based test will also be compared with other methods of predicting VTE in cancer patients which are currently in use. In the future, this blood test might be used to see if patients are at high risk of a clot during chemotherapy and provide a method to optimise the use of preventative anticoagulants in cancer patients during chemotherapy.
The group in the trial
- Cancer patients undergoing chemotherapy
Lung, ovarian and pancreatic cancer patients undergoing chemotherapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prediction and Prevention of Venous Thrombo-embolism(VTE) During Chemotherapy Using Serial Determination of Haemostasis Biomarkers.
- Plain-language title
- Blood tests to predict blood clots in people having chemotherapy for cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 15 May 2026